NCT05405244View on ClinicalTrials.gov

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

September 19, 2019

Study Completion Date

September 19, 2019

Conditions
Overweight and ObesityEating Behavior
Interventions
DRUG

Placebo

2 capsules, orally administered once

DRUG

Bromocriptine-QR

1.6mg (2 0.8mg capsules), orally administered once

Trial Locations (1)

27599

University of North Carolina, Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

American Diabetes Association

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT05405244 - Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM | Biotech Hunter | Biotech Hunter